2013’s Most Notable Stories In “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
FDA budget challenges, biosimilars, R&D revamps and social media are among stories from the past year that captured the attention of readers and reflect major biopharma trends.
You may also be interested in...
European Notebook: AstraZeneca Snuggles Up To Potential Partners In New Cambridge HQ, Viagra Patents Expire In Europe
AstraZeneca's new HQ is to cornerstone a growing U.K. cluster of clinical and research assets; the EU and U.S. start talks on what could be the world's largest free trade agreement; Viagra patent expiry provides a lift for European generic companies; European wholesalers support the liquidity of European health care markets; new pricing system for generics in Ireland.
In its most ambitious overhaul since the reorganization into iMeds in 2010, AstraZeneca’s latest R&D restructuring takes on three basic challenges: accessing innovation, improving internal productivity and reducing complexity and cost. It is the opening salvo in the new CEO’s vision for the troubled pharma.
Gregory Geba will step down March 15, saying ongoing organizational changes created challenges to implementing his vision; CDER Director Janet Woodcock will run the office during the nationwide search for a replacement.